AVITA Medical Inc
NASDAQ:RCEL
AVITA Medical Inc
NASDAQ:RCEL
Price:
8.9 USD
1.71%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
RCEL
stock under the Base Case scenario is
31.89
USD.
Compared to the current market price of 8.9 USD,
AVITA Medical Inc
is
Undervalued by 72%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RCEL
Relative Value
Base Case
31.89
USD
Undervaluation 72%
Valuation Multiples
Multiples Across Competitors
RCEL Competitors Multiples
AVITA Medical Inc Competitors
AVITA Medical Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
AVITA Medical Inc
NASDAQ:RCEL
|
228.6m USD | 4.6 | -6.5 | -4.3 | -4.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.4B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
160.6B USD | 5.4 | 42.7 | 18.2 | 29.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.6B USD | 8.1 | 27.4 | 22.1 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.7B USD | 10.5 | 28.7 | 22.9 | 24 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 168.7 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.8B USD | 9.1 | -7.8 | -8.5 | -7.6 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.2B USD | 3.3 | 27.6 | 14.1 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.2T KRW | 18.5 | 75.1 | 45.9 | 63.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
